markers to follow to assess response of bone mets to treatment

[Lani]

hopefully by "expanding role" they mean becoming readily available:

Article

Breast Cancer Research and Treatment
Publisher: Springer Netherlands
ISSN: 0167-6806 (Paper) 1573-7217 (Online)
DOI: 10.1007/s10549-005-9094-7
Issue: Volume 97, Number 1
Date: May 2006
Pages: 81 - 90
Can bone markers guide more effective treatment of bone metastases from breast cancer?
Mark Clemons1, 3 , David E.C. Cole2 and Mary C. Gainford1

(1) Division of Medical Oncology, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada
(2) Department of Clinical Pathology, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada
(3) Division of Medical Oncology, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Avenue, M4N 3M5 Toronto, Ontario, Canada
Received: 13 June 2005 Accepted: 5 October 2005 Published online: 1 December 2005

Summary Bone metastases are a common problem for breast cancer patients, causing significant disease-related morbidity and mortality. Bisphosphonates and other cancer therapies can assist in managing these patients. However, assessing treatment efficacy in bone metastases is hampered by the inability to accurately measure disease response within a clinically desirable time frame. Bone-specific biochemical markers, notably type I collagen telopeptide cross-link by-products such as N-telopeptide (NTx) and C-telopeptide (CTx), have been shown to be effective tools for assessing the severity and extent of bone metastases, and the response to bisphosphonates. Elevated NTx levels correlate with adverse clinical outcomes. Normalization of NTx and CTx excretion rates are associated with relief of symptoms and a reduced incidence of skeletal-related events (SRE). This review discusses the expanding role of these bone markers in guiding treatment of bone metastases from breast cancer.